Korro Bio, Inc. Files 8-K: Leadership and Compensation Changes
Ticker: KRRO · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1703647
| Field | Detail |
|---|---|
| Company | Korro Bio, Inc. (KRRO) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
Related Tickers: KRRO
TL;DR
Korro Bio (KRRO) filed an 8-K for leadership and comp changes. Watch for details.
AI Summary
On March 27, 2025, Korro Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated, though specific details on new appointments or compensation figures are not provided in this excerpt.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or new directions, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate governance changes, which can introduce uncertainty and affect the company's strategic direction.
Key Numbers
- 001-39062 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-2324450 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Korro Bio, Inc. (company) — Registrant
- March 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 60 First Street, 2nd Floor, Suite 250 Cambridge, MA 02141 (address) — Principal executive offices
- Frequency Therapeutics, Inc. (company) — Former company name
FAQ
What specific changes were made to the board of directors?
The filing indicates changes in directors, but the specific names and details of their departure or election are not provided in this excerpt.
Were there any changes to the company's principal officers?
The filing mentions 'Appointment of Certain Officers' as an item, suggesting potential changes, but specific details are not included in this section.
What is the nature of the 'Compensatory Arrangements of Certain Officers' mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as a topic, indicating that executive compensation is being addressed, but the specifics are not detailed here.
When was the former company name 'Frequency Therapeutics, Inc.' changed?
The date of the name change from Frequency Therapeutics, Inc. to Korro Bio, Inc. was April 12, 2017.
What is Korro Bio, Inc.'s primary business classification?
Korro Bio, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding Korro Bio, Inc. (KRRO).